Health In Tech - Class A opened higher at $0.56, compared with its previous close of $0.56. In the last trading session, the stock traded between $0.51 and $0.58. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Health In Tech - Class A is now worth
$ 10.29
Resulting in a loss of
$ 89.71 (89.71%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.03 (-6.17%)
Day High
$0.58
Day Low
$0.51
Day Open
$0.56
Prev Close
$0.56
Volume
52,853
1W Return
-12.21%
1M Return
-26.68%
3M Return
-50.24%
6M Return
-64.53%
1Y Return
-75.58%
Market Cap ($ Mn)
28
PE Ratio
-
PB Ratio
3.29
PEG Ratio
-
ROE
8.20%
ROCE
7.86%
EPS (TTM)
-
1 Week
-12.21%
1 Month
-26.68%
3 Months
-50.24%
6 Months
-64.53%
9 Months
-51.39%
Health In Tech registers 34.2 million shares for Yorkville resale
Health In Tech registered up to 34,224,247 Class A common stock shares for resale. Registration covers shares under a $20 million Standby Equity Purchase Agreement with Yorkville. Includes 9,532,889 conversion shares from promissory notes and 24,691,358 advance shares. Advance shares priced at an assumed $0.81 per share based on October 6, 2026 closing price.
24 days agoHealth In Tech launches HitRix AI platform; FY26 revenue seen at $33M
Health In Tech launched HitRix, an AI-powered platform for self-funded insurance workflows. FY26 revenue guidance revised to approximately $33 million. Revenue outlook remains roughly in line with 2025 levels. Stability attributed to timing of strategic initiatives in 2026.
1mo agoHealth In Tech files prospectus for Yorkville resale of 29.5m shares
Health In Tech filed an SEC prospectus for share resale. Yorkville is selling up to 29,532,889 shares. Transaction falls under a $20 million agreement. Proceeds will go to the selling shareholder.
2mo agoHealth In Tech Q2 loss widens as revenue dips on timing shift
Health In Tech reported a Q2 2026 loss of $(0.04) per share and revenue of $8.1 million, missing prior-year levels due to carrier transition timing. However, the company beat analyst estimates for both EPS and sales. Management highlighted $32.3 million in contracted revenue for H1 and reaffirmed full-year guidance of $45-$50 million, citing strong pipeline visibility and expanded distribution partnerships.
3mo agoHealth In Tech Latest Results: FY26 sales guidance affirmed at $45M-$50M
Health In Tech affirmed its FY2026 sales guidance at $45.000 million to $50.000 million, unchanged from its prior outlook. The analyst estimate of $46.813 million sits within the guided range. No upward or downward revision was made to the company's revenue target.
3mo agoHealth In Tech added to Russell Microcap Index on June 29
Health In Tech was added to the Russell Microcap Index effective June 29, 2026, as part of the 2026 Russell U.S. indexes reconstitution. This inclusion highlights the company's growth and market position.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $521.13 | -2.26% | $38,69,975.87M | 28.61 | |
| $172.40 | +2.12% | $3,97,675.94M | 160.64 | |
| $128.38 | +8.82% | $3,88,187.23M | 25.87 | |
| $234.10 | +0.15% | $2,87,592.79M | 28.43 | |
| $334.47 | +2.49% | $2,73,854.67M | 323.12 | |
| $248.22 | +1.51% | $2,34,597.93M | 20.94 | |
| $229.06 | +1.46% | $2,34,542.55M | 3,970.91 | |
| $149.26 | +1.81% | $1,80,374.29M | 103.31 | |
| $218.01 | +2.12% | $1,79,422.23M | 23.42 | |
| $253.66 | -1.88% | $1,49,846.35M | 15.14 | |
| $70.68 | +0.90% | $1,44,321.35M | 17.29 | |
| $306.36 | +0.30% | $1,20,938.37M | 26.28 |
An investment of $100 made 2 years ago in Health In Tech - Class A is now worth
$ 10.29
Resulting in a loss of
$ 89.71 (89.71%)
Note: Past profits do not guarantee future returns.
